A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2011
At a glance
- Drugs BMS 824393; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 14 Mar 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 Mar 2011 Planned End Date changed from 1 Jun 2013 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 09 Nov 2010 Planned end date changed from 1 Jan 2013 to 1 Jun 2013, as reported by ClinicalTrials.gov.